Sumegha Mitra

Dr. Sumegha Mitra

Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indiana University Purdue University Indianapolis (IUPUI), C547 Joseph E. Walther Hall (R3), 980 W Walnut Street, Indianapolis, IN 46202, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
YWYinu Wang
Yinu Wang
XZXingyue Zong
Xingyue Zong
SMSumegha Mitra
Sumegha Mitra
AMAnirban Kumar Mitra
Anirban Kumar Mitra
Daniela MateiDaniela Matei
Daniela Matei
Kenneth P NephewKenneth P Nephew
Kenneth P Nephew
In high-grade serous ovarian cancer (OC), chemotherapy eliminates the majority of tumor cells, leaving behind residual tumors enriched in OC stem cells (OCSC). OCSC, defined as aldehyde dehydrogenase–positive (ALDH + ), persist and contribute to tumor relapse. Inflammatory cytokine IL-6 is elevated in residual tumors after platinum treatment, and we hypothesized that IL-6 plays a critical role in platinum-induced OCSC enrichment. We demonstrate that IL-6 regulates stemness features of OCSC driven by ALDH1A1 expression and activity. We show that platinum induces IL-6 secretion by cancer-associated fibroblasts in the tumor microenvironment, promoting OCSC enrichment in residual tumors after chemotherapy. By activating STAT3 and upregulating ALDH1A1 expression, IL-6 treatment converted non-OCSC to OCSC. Having previously shown altered DNA methylation in OCSC, we show here that IL-6 induces DNA methyltransferase 1 (DNMT1) expression and the hypomethylating agent (HMA) guadecitabine induced differentiation of OCSC and reduced — but did not completely eradicate — OCSC. IL-6 neutralizing antibody (IL-6-Nab) combined with HMA fully eradicated OCSC, and the combination blocked IL-6/IL6-R/pSTAT3–mediated ALDH1A1 expression and eliminated OCSC in residual tumors that persisted in vivo after chemotherapy. We conclude that IL-6 signaling blockade combined with an HMA can eliminate OCSC after platinum treatment, supporting this strategy to prevent tumor recurrence after standard chemotherapy.

15 July 2018 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
PDF file
FPFabrizio Pin
Fabrizio Pin
RBRafael Barreto
Rafael Barreto
YKYukiko Kitase
Yukiko Kitase
SMSumegha Mitra
Sumegha Mitra
CECarlie E. Erne
Carlie E. Erne
ABAndrea Bonetto
Andrea Bonetto
Background: Cachexia frequently occurs in women with advanced ovarian cancer (OC), along with enhanced inflammation. Despite being responsible for one third of all cancer deaths, cachexia is generally under‐studied in OC due to a limited number of pre‐clinical animal models. We aimed to address this gap by characterizing the cachectic phenotype in a mouse model of OC.Methods: Nod SCID gamma mice (n = 6–10) were injected intraperitoneally with 1 × 107 ES‐2 human OC cells to mimic disseminated abdominal disease. Muscle size and strength, as well as bone morphometry, were assessed. Tumour‐derived effects on muscle fibres were investigated in C2C12 myotube cultures. IL‐6 levels were detected in serum and ascites from tumour hosts, as well as in tumour sections.Results: In about 2 weeks, ES‐2 cells developed abdominal tumours infiltrating omentum, mesentery, and adjacent organs. The ES‐2 tumours caused severe cachexia with marked loss of body weight (–12%, P < 0.01) and ascites accumulation in the peritoneal cavity (4.7 ± 1.5 mL). Skeletal muscles appeared markedly smaller in the tumour‐bearing mice (approximately –35%, P < 0.001). Muscle loss was accompanied by fibre atrophy, consistent with reduced muscle cross‐sectional area (–34%, P < 0.01) and muscle weakness (–50%, P < 0.001). Body composition assessment by dual‐energy X‐ray absorptiometry revealed decreased bone mineral density (–8%, P < 0.01) and bone mineral content (–19%, P < 0.01), also consistent with reduced trabecular bone in both femurs and vertebrae, as suggested by micro‐CT imaging of bone morphometry. In the ES‐2 mouse model, cachexia was also associated with high tumour‐derived IL‐6 levels in plasma and ascites (26.3 and 279.6 pg/mL, respectively) and with elevated phospho‐STAT3 (+274%, P < 0.001), reduced phospho‐AKT (–44%, P < 0.001) and decreased mitochondrial proteins, as well as with increased protein ubiquitination (+42%, P < 0.001) and expression of ubiquitin ligases in the skeletal muscle of tumour hosts. Similarly, ES‐2 conditioned medium directly induced fibre atrophy in C2C12 mouse myotubes (–16%, P < 0.001), consistent with elevated phospho‐STAT3 (+1.4‐fold, P < 0.001) and altered mitochondrial homoeostasis and metabolism, while inhibition of the IL‐6/STAT3 signalling by means of INCB018424 was sufficient to restore the myotubes size.Conclusions: Our results suggest that the development of ES‐2 OC promotes muscle atrophy in both in vivo and in vitro conditions, accompanied by loss of bone mass, enhanced muscle protein catabolism, abnormal mitochondrial homoeostasis, and elevated IL‐6 levels. Therefore, this represents an appropriate model for the study of OC cachexia. Our model will aid in identifying molecular mediators that could be effectively targeted in order to improve muscle wasting associated with OC.

27 April 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
JHJames Haley
James Haley
STSunil Tomar
Sunil Tomar
NPNicholas Pulliam
Nicholas Pulliam
SXSen Xiong
Sen Xiong
SPSusan M. Perkins
Susan M. Perkins
Anriban MitraAnriban Mitra
Anriban Mitra
Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease

5 January 2009 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
NMNuala J. Meyer
Nuala J. Meyer
YHYong Huang
Yong Huang
PSPatrick A. Singleton
Patrick A. Singleton
SSSaad Sammani
Saad Sammani
JMJaideep Moitra
Jaideep Moitra
JGJoe G. N. Garcia
Joe G. N. Garcia
We explored the mechanistic involvement of the growth arrest and DNA damage‐inducible gene GADD45a in lipopolysaccharide (LPS)‐ and ventilator‐induced inflammatory lung injury (VILI). Multiple biochemical and genomic parameters of inflammatory lung injury indicated that GADD45a –/– mice are modestly susceptible to intratracheal LPS‐induced lung injury and profoundly susceptible to high tidal volume VILI, with increases in microvascular permeability and bronchoalveolar lavage levels of inflammatory cytokines. Expression profiling of lung tissues from VILI‐ challenged GADD45a –/– mice revealed strong dysregulation in the B‐cell receptor signaling pathway compared with wild‐type mice and suggested the involvement of PI3 kinase/Akt signaling components. Western blot analyses of lung homogenates confirmed ~50% reduction in Akt protein levels in GADD45a –/– mice accompanied by marked increases in Akt ubiquitination. Electrical resistance measurements across human lung endothelial cell monolayers with either reduced GADD45a or Akt expression (siRNAs) revealed significant potentiation of LPS‐induced human lung endothelial barrier dysfunction, which was attenuated by over‐expression of a constitutively active Aktl transgene. These studies validate GADD45a as a novel candidate gene in inflammatory lung injury and a significant participant in vascular barrier regulation via effects on Akt‐mediated endothelial signaling.— Meyer, N. J., Huang, Y., Singleton, P. A., Sammani, S., Moitra, J., Evenoski, C. L., Husain, A. N., Mitra, S., Moreno‐ Vinasco, L., Jacobson, J. R., Lussier, Y. A., Garcia, J. G. N. GADD45a is a novel candidate gene in inflammatory lung injury via influences on Akt signaling. FASEBJ. 23, 1325–1337 (2009)

1 August 2006 in Maturitas
Verified
Journal Article
Closed access
SMSumegha Mitra
Sumegha Mitra
MDMeena Desai
Meena Desai
MKM. Ikram Khatkhatay
M. Ikram Khatkhatay

9 October 2019 in Cancers
Verified
Journal Article
Open access
PDF file
SMSumegha Mitra
Sumegha Mitra
KTKartikeya Tiwari
Kartikeya Tiwari
RPRam Podicheti
Ram Podicheti
TPTaruni Pandhiri
Taruni Pandhiri
DRDouglas B. Rusch
Douglas B. Rusch
Anriban MitraAnriban Mitra
Anriban Mitra
Background: Ovarian cancer is the most lethal gynecologic malignancy. There is a lack of comprehensive investigation of disease initiation and progression, including gene expression changes during early metastatic colonization. Methods: RNA-sequencing (RNA-seq) was done with matched primary tumors and fallopian tubes (n = 8 pairs) as well as matched metastatic and primary tumors (n = 11 pairs) from ovarian cancer patients. Since these are end point analyses, it was combined with RNA-seq using high-grade serous ovarian cancer cells seeded on an organotypic three-dimensional (3D) culture model of the omentum, mimicking early metastasis. This comprehensive approach revealed key changes in gene expression occurring in ovarian cancer initiation and metastasis, including early metastatic colonization. Results: 2987 genes were significantly deregulated in primary tumors compared to fallopian tubes, 845 genes were differentially expressed in metastasis compared to primary tumors and 304 genes were common to both. An assessment of patient metastasis and 3D omental culture model of early metastatic colonization revealed 144 common genes that were altered during early colonization and remain deregulated even in the fully developed metastasis. Deregulation of the matrisome was a key process in early and late metastasis. Conclusion: These findings will help in understanding the key pathways involved in ovarian cancer progression and eventually targeting those pathways for therapeutic interventions.